Progresses in polymeric nanoparticles for delivery of tyrosine kinase inhibitors

被引:45
|
作者
Foroughi-Nia, Behrouz [1 ,2 ]
Barar, Jaleh [2 ,3 ]
Memar, Mohammad Yousef [4 ]
Aghanejad, Ayuob [2 ]
Davaran, Soudabeh [1 ,2 ]
机构
[1] Tabriz Univ Med Sci, Fac Pharm, Dept Med Chem, Tabriz, Iran
[2] Tabriz Univ Med Sci, Res Ctr Pharmaceut Nanotechnol, Biomed Inst, Tabriz, Iran
[3] Tabriz Univ Med Sci, Fac Pharm, Dept Pharmaceut, Tabriz, Iran
[4] Tabriz Univ Med Sci, Infect & Trop Dis Res Ctr, Tabriz, Iran
基金
美国国家科学基金会;
关键词
Tyrosine kinase inhibitor; Theranostic agent; Cancer therapy; Nanotechnology; TARGETED DELIVERY; SYNERGISTIC THERAPY; DRUG-DELIVERY; CO-DELIVERY; ERLOTINIB; SORAFENIB; DOXORUBICIN; CARCINOMA; GEFITINIB; PACLITAXEL;
D O I
10.1016/j.lfs.2021.119642
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Tyrosine kinase inhibitors (TKIs), as an important class of chemotherapeutic drugs, induce apoptosis by altering the path of the cellular signal, resulting in cell death. However, some chemotherapeutic drugs have a limited therapeutic index and are usually destructive as well as unpredictable. In addition, the limitation of early diagnosis and inefficiency of some of the drugs in ordinary treatments lead to disease progression and decreases in the survival of cancer patients. For this purpose, various methods have been proposed, among them, nanomedicine has transpired as a modern approach for the treatment of multiple cancers. Over the last two decades, targeted therapy has been developed for cancer-specific cells/tissues and has rather restricted nonselective toxicities. In vivo and in vitro studies demonstrated nanoparticles (NPs), nano-scale drugs, and nano-carriers alone or in combination with other therapeutic, imaging, and theranostic agents would be applied as an effective approach targeting a diversity of malignant tissue. Therefore, using the latest advances in materials science and biomaterials, biology, it has happened that general diagnosis and treatment can be performed. In this review, we indicated the applications of theranostic nano-polymer and nano-liposome to TKIs delivery.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Recent progress in drug delivery systems for tyrosine kinase inhibitors in the treatment of lung cancer
    Aktas, Pelinsu Korucu
    Baysal, Ipek
    Yabanoglu-Ciftci, Samiye
    Lamprecht, Alf
    Arica, Betul
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2024, 650
  • [2] Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy
    Zhou, Xiaohan
    Shi, Kun
    Hao, Ying
    Yang, Chengli
    Zha, Ruoyu
    Yi, Cheng
    Qian, Zhiyong
    ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 15 (01) : 26 - 41
  • [3] Nanomedicine of tyrosine kinase inhibitors
    Smidova, Veronika
    Michalek, Petr
    Goliasova, Zita
    Eckschlager, Tomas
    Hodek, Petr
    Adam, Vojtech
    Heger, Zbynek
    THERANOSTICS, 2021, 11 (04): : 1546 - 1567
  • [4] Controlled Tyrosine Kinase Inhibitor Delivery to Liver Cancer Cells by Gate-Capped Mesoporous Silica Nanoparticles
    Sedighi, Mahsa
    Rahimi, Fereshteh
    Shahbazi, Mohammad-Ali
    Rezayan, Ali Hossein
    Kettiger, Helene
    Einfalt, Tomaz
    Huwyler, Joerg
    Witzigmann, Dominik
    ACS APPLIED BIO MATERIALS, 2020, 3 (01): : 239 - 251
  • [5] Novel Approaches for Efficient Delivery of Tyrosine Kinase Inhibitors
    Moradpour, Zahra
    Barghi, Leila
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2019, 22 : 37 - 48
  • [6] Tyrosine Kinase Inhibitors for the Elderly
    Hohenforst-Schmidt, Wolfgang
    Zarogoulidis, Paul
    Steinheimer, Michael
    Benhassen, Naim
    Tsiouda, Theodora
    Baka, Sofia
    Yarmus, Lonny
    Stratakos, Grigoris
    Organtzis, John
    Pataka, Athanasia
    Tsakiridis, Kosmas
    Karapantzos, Ilias
    Karapantzou, Chrysanthi
    Darwiche, Kaid
    Zissimopoulos, Athanasios
    Pitsiou, Georgia
    Zarogoulidis, Konstantinos
    Man, Yan-Gao
    Rittger, Harald
    JOURNAL OF CANCER, 2016, 7 (06): : 687 - 693
  • [7] Drug delivery, biodistribution and anti-EGFR activity: theragnostic nanoparticles for simultaneous in vivo delivery of tyrosine kinase inhibitors and kinase activity biosensors
    Bofinger, Robin
    Weitsman, Gregory
    Evans, Rachel
    Glaser, Matthias
    Sander, Kerstin
    Allan, Helen
    Hochhauser, Daniel
    Kalber, Tammy L.
    Arstad, Erik
    Hailes, Helen C.
    Ng, Tony
    Tabor, Alethea B.
    NANOSCALE, 2021, 13 (44) : 18520 - 18535
  • [8] Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives
    Rashmi R. Shah
    Joel Morganroth
    Devron R. Shah
    Drug Safety, 2013, 36 : 491 - 503
  • [9] An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors
    Cheng, Chao
    Zhao, Yanding
    Schaafsma, Evelien
    Weng, Yi-Lan
    Amos, Christopher
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (09) : 2621 - 2633
  • [10] Tyrosine kinase inhibitors
    Hantraye, Benedicte
    Leroux, Amelie
    Clere, Nicolas
    ACTUALITES PHARMACEUTIQUES, 2015, 54 (551): : 22 - 27